Xanthine oxidase inhibitor / Urate-lowering therapy
Pregnancy: Avoid unless essential. Limited data. Consider stopping and using conservative management.
Allopurinol
Brand names: Zyloric
Adult dose
Dose: 100 mg daily initially; titrate to serum urate <360 micromol/L (target <300 if tophi)
Route: Oral (after meals)
Frequency: Once daily
Max: 900 mg/day
Start 100 mg/day. Increase by 100 mg every 4 weeks. Target serum urate <360 micromol/L (or <300 with tophi). DO NOT start during acute gout attack. Cover first 3–6 months with colchicine 500 mcg OD or low-dose NSAID to prevent flare. Adequate hydration.
Paediatric dose
Dose: 10 mg/kg
Route: Oral
Frequency: Once daily
Max: 400 mg/day
<15 years (tumour lysis prophylaxis): 10–20 mg/kg/day in 2–3 divided doses (max 400 mg/day). 6–12 years: 150 mg/day. <6 years: 150 mg/day. Gout prophylaxis in children: specialist guidance.
Dose adjustments
Renal
eGFR 10–20: max 100 mg/day; eGFR <10: 50–100 mg with increased interval; haemodialysis: 100 mg after each session.
Hepatic
Reduce dose in severe hepatic impairment.
Paediatric weight-based calculator
<15 years (tumour lysis prophylaxis): 10–20 mg/kg/day in 2–3 divided doses (max 400 mg/day). 6–12 years: 150 mg/day. <6 years: 150 mg/day. Gout prophylaxis in children: specialist guidance.
Clinical pearls
- NEVER start during an acute gout attack — wait 2–4 weeks after attack resolves
- Prophylactic colchicine essential for first 3–6 months of ULT to prevent flares
- HLA-B*5801 allele — associated with severe cutaneous reactions in Han Chinese/Thai — screen before starting
- Critical interaction: azathioprine + allopurinol — reduce aza dose to 25% of normal
- Check serum urate every 4 weeks during titration; target <360 micromol/L
Contraindications
- Acute gout attack (do not initiate — wait until attack resolved for 2–4 weeks)
Side effects
- Gout flare on initiation (paradoxical — use prophylaxis)
- Rash (stop immediately — can progress to Stevens-Johnson Syndrome or TEN)
- GI upset
- Hypersensitivity syndrome (DRESS) — rare but serious
- Elevated LFTs
Interactions
- Azathioprine/mercaptopurine — MAJOR: allopurinol inhibits xanthine oxidase, causing 4× increase in azathioprine levels (reduce azathioprine by 75%)
- Ampicillin/amoxicillin — increased rash frequency
- Warfarin — increased anticoagulant effect
- Theophylline — increased levels
- Ciclosporin — increased ciclosporin levels
Monitoring
- Serum urate (every 4 weeks during titration then 6-monthly)
- LFTs and U&E (baseline and periodically)
- Rash and skin reactions (especially in first weeks)
Reference: BNFc; BNF; NICE NG219 Gout; BSR Gout Guidelines; EULAR 2022. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy
- ACC/AHA Pooled Cohort Equations (ASCVD Risk) · Cardiovascular Risk
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- DAPT Decision Tool (Ticagrelor vs Clopidogrel) · Antiplatelet Therapy
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Travis Criteria for Severe Ulcerative Colitis · Inflammatory Bowel Disease
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022